Demographic and clinical features of the patients with <i>de novo</i> malignancy.

HCC, hepatocellular carcinoma; HBV, hepatitis B virus; LC, liver cirrhosis; LDLT, living donor liver transplantation; FK, tacrulimus; MMF, mycophenolate mofetil; PTLD, post-transplant lymphoproliferative disorders; MDS-RAEB, Myelodysplastic syndromes-refractory anemia with excess blasts; AML, acute myeloid leukemia; CTx, chemotherapy; RTx, radiotherapy; OP, operation; TACE, transcatheter arterial chemoembolization; RFA, radiofrequency ablation; *Time period from liver transplantation to de novo cancer; #time period from the diagnosis of de novo cancer to last follow-up.